Centessa Pharmaceuticals plc (CNTA) Revenue History
Annual and quarterly revenue from 2020 to present
CNTA Revenue Over Time (2020–2025)
CNTA Revenue Growth History
0 of 1 years with positive growth- FY2020 revenue growth
- N/A
- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- N/A
- FY2023 revenue growth
- N/A
- FY2024 revenue growth
- -100.0%
- FY2025 revenue growth
- N/A
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $0 | -100.0% |
| Q4 2025 | $0 | — |
| Q3 2025 | $0 | — |
| Q2 2025 | $0 | — |
| Q1 2025 | $15.0M | — |
| Q4 2024 | $0 | -100.0% |
| Q3 2024 | $0 | — |
| Q2 2024 | $0 | — |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
CNTA's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
CNTA Revenue Analysis (2020–2025)
Current Revenue & Growth
As of June 12, 2026, Centessa Pharmaceuticals plc (CNTA) generated trailing twelve-month (TTM) revenue of $0, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q1 2026) recorded $0 in revenue
Historical Growth Trajectory
CNTA's historical revenue data shows various trends over time. Centessa Pharmaceuticals plc's highest annual revenue of $15.0 million was recorded in 2025, an all-time high.
Revenue by Segment
CNTA's revenue is primarily driven by Reportable Segment (100%). With over half of revenue concentrated in Reportable Segment, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including KYMR (-12.6% YoY), and ARQT (+95.3% YoY) — CNTA has underperformed the peer group in revenue growth. Compare CNTA vs KYMR →
CNTA Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
 CNTACurrent | $0 | -100.0% | - | -1384.6% | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% | |
 ARQT | $376M | +95.3% | - | -3.3% |
CNTA Historical Revenue Data (2020–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $15.0M | - | $15.0M | 100.0% | $-207,692,000 | -1384.6% |
| 2024 | $0 | -100.0% | $0 | - | $-201,055,000 | - |
| 2023 | $6.9M | - | $6.9M | 100.0% | $-171,283,000 | -2499.4% |
| 2022 | $0 | - | $0 | - | $-212,263,000 | - |
| 2021 | $0 | - | $0 | - | $-374,867,000 | - |
| 2020 | $0 | - | $0 | - | $-10,440,000 | - |
What if you invested $1,000 in CNTA back in 2020?
Total return with dividends reinvested · 6+ years of data
Calculate ReturnsHow much would $100/month in CNTA be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs CNTA Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCNTA vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowCNTA — Frequently Asked Questions
Quick answers to the most common questions about buying CNTA stock.
Is CNTA's revenue growth accelerating or slowing?
CNTA revenue is declining -100.0% year-over-year. TTM revenue fell to $0.00, contrasting with the 5-year CAGR of N/A. The reversal reflects either macro headwinds or company-specific challenges.
What is CNTA's revenue history from 2020 to 2026?
Centessa Pharmaceuticals plc (CNTA) revenue history spans 2020 to 2026. TTM revenue as of 2026 is $0.00, growing at -100.0% YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is CNTA's long-term revenue growth rate (CAGR)?
Centessa Pharmaceuticals plc's 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of -100.0% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for CNTA.
Why does CNTA's quarterly revenue fluctuate?
CNTA quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Centessa Pharmaceuticals plc's revenue data from 2020 to 2026 shows full historical quarterly detail on this page.
How is CNTA's revenue distributed by segment?
CNTA reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does CNTA's revenue compare to industry peers?
Centessa Pharmaceuticals plc (CNTA) with TTM revenue of $0.00 and -100.0% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.